Estradiol/norethisterone

Estradiol/norethisterone
	Estradiol
	Norethisterone
Combination of
Estradiol	Estrogen
Norethisterone	Progestogen; Progestin
Clinical data
Other names	E2/NET; Netagen; Netagen 403
Routes of; administration	By mouth
Drug class	Estrogen; Progestin; Progestogen
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	62057-27-6;

Estradiol/norethisterone (E2/NET), tentative brand name Netagen or Netagen 403, was a combination of estradiol (E2), an estrogen, and norethisterone (NET), a progestin, which was studied as a birth control pill to prevent pregnancy in women.^[1]^[2]^[3]^[4]^[5] It was taken by mouth and contained 4 mg micronized E2 and 3 mg NET per tablet.^[2]^[3] The medication was developed by Novo Pharmaceuticals in Denmark and was never marketed.^[1]^[2]^[3]

Two related formulations were Netagen 423 (4 mg estradiol, 2 mg estriol, 3 mg norethisterone) and Netasyn (50 μg ethinylestradiol, 3 mg norethisterone), were also studied but never marketed.^[1]^[3]^[4]

References

^ ^a ^b ^c Fruzzetti F, Bitzer J (January 2010). "Review of clinical experience with estradiol in combined oral contraceptives". Contraception. 81 (1): 8–15. doi:10.1016/j.contraception.2009.08.010. PMID 20004267.
^ ^a ^b ^c Astedt B, Svanberg L, Jeppsson S, Liedholm P, Rannevik G (January 1977). "The natural oestrogenic hormone oestradiol as a new component of combined oral contraceptives". Br Med J. 1 (6056): 269. doi:10.1136/bmj.1.6056.269. PMC 1604185. PMID 319864.
^ ^a ^b ^c ^d Astedt B, Jeppsson S, Liedholm P, Rannevik G, Svanberg L (September 1979). "Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17 beta-oestradiol". Br J Obstet Gynaecol. 86 (9): 732–6. doi:10.1111/j.1471-0528.1979.tb11276.x. PMID 387069. S2CID 72299078.
^ ^a ^b Samsioe G, Skryten A, Silfverstolpe G (1983). "Oral contraception with a nonalkylated estrogen component. Effects on lipid metabolism". Gynecol. Obstet. Invest. 15 (5): 275–82. doi:10.1159/000299421. PMID 6852647.
^ Skouby SO, Jensen BM, Kühl C, Mølsted-Pedersen L, Svenstrup B, Nielsen J (July 1985). "Hormonal contraception in diabetic women: acceptability and influence on diabetes control and ovarian function of a nonalkylated estrogen/progestogen compound". Contraception. 32 (1): 23–31. doi:10.1016/0010-7824(85)90113-1. PMID 4053603.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

[pmid20004267-1] Fruzzetti F, Bitzer J (January 2010). "Review of clinical experience with estradiol in combined oral contraceptives". Contraception. 81 (1): 8–15. doi:10.1016/j.contraception.2009.08.010. PMID 20004267.

[pmid319864-2] Astedt B, Svanberg L, Jeppsson S, Liedholm P, Rannevik G (January 1977). "The natural oestrogenic hormone oestradiol as a new component of combined oral contraceptives". Br Med J. 1 (6056): 269. doi:10.1136/bmj.1.6056.269. PMC 1604185. PMID 319864.

[pmid387069-3] Astedt B, Jeppsson S, Liedholm P, Rannevik G, Svanberg L (September 1979). "Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17 beta-oestradiol". Br J Obstet Gynaecol. 86 (9): 732–6. doi:10.1111/j.1471-0528.1979.tb11276.x. PMID 387069. S2CID 72299078.

[pmid6852647-4] Samsioe G, Skryten A, Silfverstolpe G (1983). "Oral contraception with a nonalkylated estrogen component. Effects on lipid metabolism". Gynecol. Obstet. Invest. 15 (5): 275–82. doi:10.1159/000299421. PMID 6852647.

[pmid4053603-5] Skouby SO, Jensen BM, Kühl C, Mølsted-Pedersen L, Svenstrup B, Nielsen J (July 1985). "Hormonal contraception in diabetic women: acceptability and influence on diabetes control and ovarian function of a nonalkylated estrogen/progestogen compound". Contraception. 32 (1): 23–31. doi:10.1016/0010-7824(85)90113-1. PMID 4053603.

[1]

[2]

[3]

[4]

[5]

See also

References